Cephalon invests $20M in Acusphere

11/5/2008 | American City Business Journals

Cephalon will invest $20 million in Acusphere, gaining an exclusive worldwide license to AI-525 -- an injectable version of celecoxib, an anti-inflammatory drug. The investment also allows Cephalon to license Acusphere's blood-imaging agent Imagify, which is pending FDA approval.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC